<DOC>
	<DOCNO>NCT01013987</DOCNO>
	<brief_summary>Phase 4 , single arm , open label study design compare safety efficacy antiviral activity immunological effect Maraviroc combination Raltegravir Darunavir/Ritonavir treatment triple class failure adult HIV-1 infected subject . The purpose study look safety efficacy combination 3 new antiretroviral drug : maraviroc , darunavir raltegravir patient multi-resistant virus limit treatment option . Patients undergo treatment 48 week ; safety virological efficacy preliminary evaluate week 16 24 .</brief_summary>
	<brief_title>Maraviroc ( Celsentri ) With Raltegravir Darunavir/Ritonavir Treatment Triple Class Failure Adult HIV-1 Infected Patients</brief_title>
	<detailed_description>This Phase 4 , single arm , open-label , study design demonstrate safety , tolerability , efficacy , antiviral immunological activity Maraviroc combination Raltegravir Darunavir/Ritonavir patient limit treatment option HIV-1 infected subject ≥ 21 year old . The trial population comprise 60 HIV-infected subject history triple class antiretroviral failure , naïve CCR5-inhibitors , integrase-inhibitors darunavir evaluate . Single arm , stratify accord plasma viral load screening ( &gt; &lt; 100,000 copies/ml ) . Those evidence R5 viruses susceptibility darunavir resistance test analysis , plus history failure NRTIs , NNRTIs least one PI , plus genotype analysis show evidence resistance NRTIs ( least 2 TAMS and/or Q151M 69ss ) , resistance PIs ( least 2 major mutation ) , start regimen maraviroc , raltegravir ritonavir boost darunavir . This trial consist screen period 6 week , 48-week treatment period , interim analysis 16 24 week . Followed 4-week post-treatment follow-up ( FU ) period . Virologic response , CD4 count change , clinical outcome safety follow throughout study .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Male female subject least 21 year age . 2 . Patient document HIV1 infection define positive ELISA plus confirmatory Western Blot ; alternatively , plasma HIV RNA ≥10,000 copies/ml ever document . 3 . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . 4 . Subject agrees take medication study , include counter medicine , vitamin , mineral , herbal preparation , alcohol recreational drug without approval trial physician . 5 . Documented HIV RNA &gt; 500 copies/ml 6 . Subject triple class antiretroviral failure ( NRTI , NNRTI , PI ) 7 . Subject naïve CCR5inhibitors , integraseinhibitors darunavir . 8 . Subjects comply protocol requirement . 9 . Subject 's general medical condition , investigator 's opinion , interfere assessment completion trial . 10 . If female , subject must either postmenopausal least one year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , must : 1. use double birth control method include least one barrier method , acceptable subject investigator , 2. urine pregnancy test perform Screening Visit Baseline , result test must negative . 3. continue practice birth control method least 30 day end treatment period . 11 . Subject present R5 HIV1 Screening , verify Trofile Essay Monogram Bioscience . 1 . Evidence resistance Maraviroc , Raltegravir , Darunavir/Ritonavir , base resistance test perform Screening . 2 . Previously document HIV2 infection . 3 . Use disallow concomitant therapy list guideline use drug . 4 . Patient current ( active ) diagnosis acute hepatitis due cause OR chronic hepatitis B and/or C WITH aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 5 x upper limit normal ( ULN ) AND/OR likely require treatment next year . 5 . Any active clinically significant disease ( e.g . tuberculosis , cardiac disfunction , pancreatitis ) finding screen medical history physical examination , investigator´s opinion , would compromise subject´s safety outcome trial adherence trial protocol . 6 . Subject currently active AIDS defining illness ( Category C condition accord CDC Classification System HIV infection 1993 ) within 30 day screen . Subjects stable maintenance therapy opportunistic infection may enrol . 7 . Life expectancy &lt; 1 year accord judgment investigator . 8 . Screening laboratory analysis show follow abnormal laboratory result : 1 . Hemoglobin &lt; 8.0 g/dL 2 . Absolute neutrophil count &lt; 750 cells/µL 3 . Platelet count &lt; 50,000 mm3 9 . Subject enrol clinical trial include blood sampling , specimen collection , interventional procedure . Concurrent participation noninterventional observational trial 10 . Use investigational agent within 30 day prior screen . 11 . Use immunosuppressive drug , cytokine inhibitor cytokine last year . 12 . Any condition ( include limit alcohol drug use ) opinion investigator , could compromise subject 's safety adherence protocol ; . 13 . Subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>triple class failure</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Darunavir/ritonavir</keyword>
	<keyword>Maraviroc raltegravir darunavir/ritonavir</keyword>
</DOC>